Anika Therapeutics, Inc.
ANIK
$9.72
-$0.04-0.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 41.34% | 18.53% | -- | -- | -- |
| Total Depreciation and Amortization | 10.73% | -20.41% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -46.65% | 85.58% | -- | -- | -- |
| Change in Net Operating Assets | 215.05% | -1,324.91% | -- | -- | -- |
| Cash from Operations | 3,734.92% | -45.38% | -- | -- | 569.22% |
| Capital Expenditure | -28.63% | 48.05% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -100.00% | -- | -- | -- | -- |
| Other Investing Activities | 104.34% | -179.36% | -- | -- | -- |
| Cash from Investing | -221.34% | -132.24% | -- | -- | 46.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | 84.15% | 98.49% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -107.26% | 103.29% | -- | -- | -259.23% |
| Foreign Exchange rate Adjustments | -187.54% | 219.44% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,464.22% | 94.61% | -- | -- | 92.18% |